Gene · 6580
Papers3,731
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 3,731
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia. | Front Oncol | 2023 | 38269022 | PubTator, text mining | PubMed |
| Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins. | Pharmaceutics | 2023 | 38258074 | PubTator, text mining | PubMed |
| Recent Advances in the Gastrointestinal Complex in Vitro Model for ADME Studies. | Pharmaceutics | 2023 | 38258048 | PubTator, text mining | PubMed |
| Assessment of Some Unsymmetrical Porphyrins as Promising Molecules for Photodynamic Therapy of Cutaneous Disorders. | Pharmaceuticals (Basel) | 2023 | 38256895 | PubTator, text mining | PubMed |
| Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer. | Curr Issues Mol Biol | 2023 | 38248312 | PubTator, text mining | PubMed |
| Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer. | Curr Oncol | 2023 | 38248100 | PubTator, text mining | PubMed |
| Mass Spectrometry Study about In Vitro and In Vivo Reaction between Metformin and Glucose: A Preliminary Investigation on Alternative Biological Behavior. | Int J Mol Sci | 2023 | 38203351 | PubTator, text mining | PubMed |
| Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α. | Oncol Res | 2023 | 38188684 | PubTator, text mining | PubMed |
| Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives. | Pharmaceutics | 2023 | 38140105 | PubTator, text mining | PubMed |
| Metformin: The Winding Path from Understanding Its Molecular Mechanisms to Proving Therapeutic Benefits in Neurodegenerative Disorders. | Pharmaceuticals (Basel) | 2023 | 38139841 | PubTator, text mining | PubMed |
| Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers in vitro. | Front Endocrinol (Lausanne) | 2023 | 38116319 | PubTator, text mining | PubMed |
| Microbiome differences related to metformin intolerance among Black individuals with diabetes, a pilot cross-sectional study. | Metabol Open | 2023 | 38115865 | PubTator, text mining | PubMed |
| Structural Dynamics of P-Rex1 Complexed with Natural Leads Establishes the Protein as an Attractive Target for Therapeutics to Suppress Cancer Metastasis. | Biomed Res Int | 2023 | 38098889 | PubTator, text mining | PubMed |
| Potential anticancer properties and mechanisms of thymoquinone in colorectal cancer. | Cancer Cell Int | 2023 | 38087345 | PubTator, text mining | PubMed |
| Stereoselectivity in Cell Uptake by SLC22 Organic Cation Transporters 1, 2, and 3. | J Med Chem | 2023 | 38052451 | PubTator, text mining | PubMed |
| Predictors of gastrointestinal complaints in patients on metformin therapy. | Open Med (Wars) | 2023 | 38045859 | PubTator, text mining | PubMed |
| Mitochondrial-targeted antioxidant attenuates preeclampsia-like phenotypes induced by syncytiotrophoblast-specific Gαq signaling. | Sci Adv | 2023 | 38039359 | PubTator, text mining | PubMed |
| Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations. | Diabetes Metab Syndr Obes | 2023 | 38028995 | PubTator, text mining | PubMed |
| SLC22A3 that encodes organic cation transporter-3 is associated with prognosis and immunogenicity of human lung squamous cell carcinoma. | Transl Lung Cancer Res | 2023 | 38025816 | PubTator, text mining | PubMed |
| Revisiting ameloblastin; addressing the EMT-ECM axis above and beyond oral biology. | Front Cell Dev Biol | 2023 | 38020879 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6580/papers?page=10